NasdaqGS:MASI

Stock Analysis Report

Executive Summary

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Masimo's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.3%

MASI

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

23.7%

MASI

9.5%

US Medical Equipment

1.1%

US Market

MASI outperformed the Medical Equipment industry which returned 9.9% over the past year.

MASI outperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

MASIIndustryMarket
7 Day0.3%0.7%-0.2%
30 Day0.2%0.1%2.5%
90 Day4.9%2.5%1.6%
1 Year23.7%23.7%10.4%9.5%3.4%1.1%
3 Year153.5%153.5%69.3%64.1%45.2%35.8%
5 Year618.4%618.4%138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Masimo's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Masimo undervalued based on future cash flows and its price relative to the stock market?

40.43x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Masimo's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Masimo's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Masimo is good value based on earnings compared to the US Medical Equipment industry average.

Masimo is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Masimo is poor value based on expected growth next year.


Price Based on Value of Assets

Masimo is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Masimo expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

13.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Masimo's revenue is expected to grow by 9.6% yearly, however this is not considered high growth (20% yearly).

Masimo's earnings are expected to grow by 13.4% yearly, however this is not considered high growth (20% yearly).

Masimo's revenue growth is expected to exceed the United States of America market average.

Masimo's earnings growth is positive but not above the United States of America market average.

Masimo's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Masimo is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Masimo performed over the past 5 years?

20.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Masimo has delivered over 20% year on year earnings growth in the past 5 years.

Masimo's 1-year earnings growth exceeds its 5-year average (68.6% vs 20.9%)

Masimo's earnings growth has exceeded the US Medical Equipment industry average in the past year (68.6% vs 28.2%).


Return on Equity

Masimo has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Masimo used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Masimo's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Masimo's financial position?


Financial Position Analysis

Masimo is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Masimo's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Masimo has no debt.

Masimo has no debt compared to 5 years ago when it was 23.9%.

Masimo has no debt, it does not need to be covered by operating cash flow.

Masimo has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Masimo has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Masimo's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Masimo's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Masimo's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Masimo has not reported any payouts.

Unable to verify if Masimo's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Masimo has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Masimo's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Masimo's salary, the management and board of directors tenure and is there insider trading?

5.5yrs

Average management tenure


CEO

Joe Kiani (54yo)

30.7yrs

Tenure

US$15,047,156

Compensation

Mr. Joseph E. Kiani, also known as Joe, founded Masimo Corporation in 1989 and has been its Chairman and Chief Executive Officer since 1989. Mr. Kiani serves as the Chairman and Chief Executive Officer of  ...


CEO Compensation Analysis

Joe's remuneration is higher than average for companies of similar size in United States of America.

Joe's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.5yrs

Average Tenure

54yo

Average Age

The average tenure for the Masimo management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

3.8yrs

Average Tenure

68yo

Average Age

The tenure for the Masimo board of directors is about average.


Insider Trading

Masimo individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$1,052,73023 Aug 19
Sanford Fitch
EntityIndividual
Role
Member of the Board of Directors
Director
Shares7,000
Max PriceUS$150.39

Ownership Breakdown


Management Team

  • Joe Kiani (54yo)

    Founder

    • Tenure: 30.7yrs
    • Compensation: US$15.05m
  • Eli Kammerman

    Vice President of Business Development & Investor Relations

    • Tenure: 10.3yrs
  • Anand Sampath (53yo)

    Executive Vice President of Operations & Clinical Research

    • Tenure: 0.3yrs
    • Compensation: US$2.00m
  • Yongsam Lee (54yo)

    Executive VP & Chief Information Officer

    • Tenure: 17.4yrs
    • Compensation: US$1.49m
  • Steven Barker (74yo)

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$311.67k
  • Jon Coleman (55yo)

    President of Worldwide Sales

    • Tenure: 8.6yrs
    • Compensation: US$1.78m
  • David Van Ramshorst (58yo)

    Chief Accounting Officer & Senior VP of Finance

    • Tenure: 4.6yrs
  • Tom McClenahan (46yo)

    Executive VP

    • Tenure: 6.4yrs
    • Compensation: US$1.80m
  • Micah Young (40yo)

    Executive VP of Finance & CFO

    • Tenure: 1.9yrs
    • Compensation: US$1.88m
  • Bilal Muhsin (38yo)

    Executive VP of Marketing & Regulatory Affairs and COO

    • Tenure: 0.3yrs
    • Compensation: US$2.02m

Board Members

  • Craig Reynolds (70yo)

    Director

    • Tenure: 5.4yrs
    • Compensation: US$219.33k
  • Joe Kiani (54yo)

    Founder

    • Tenure: 30.7yrs
    • Compensation: US$15.05m
  • Sandy Fitch (78yo)

    Director

    • Tenure: 12.8yrs
    • Compensation: US$227.75k
  • Julie Shimer (66yo)

    Director

    • Tenure: 0.7yrs
  • Steven Barker (74yo)

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$311.67k
  • H. Cohen (54yo)

    Director

    • Tenure: 1.1yrs
  • Tom Harkin (80yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$212.44k
  • Adam Mikkelson (41yo)

    Director

    • Tenure: 2.9yrs
    • Compensation: US$212.44k

Company Information

Masimo Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Masimo Corporation
  • Ticker: MASI
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$8.079b
  • Shares outstanding: 53.33m
  • Website: https://www.masimo.com

Number of Employees


Location

  • Masimo Corporation
  • 52 Discovery
  • Irvine
  • California
  • 92618
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MASINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2007
3M4DB (Deutsche Boerse AG)YesCommon StockDEEURAug 2007
0JZ2LSE (London Stock Exchange)YesCommon StockGBUSDAug 2007
MASI *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNAug 2007

Biography

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oxime ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:16
End of Day Share Price2019/09/19 00:00
Earnings2019/06/29
Annual Earnings2018/12/29


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.